What is 3Derm?
3Derm operates at the intersection of medical imaging and artificial intelligence, providing a comprehensive suite of teledermatology solutions designed to optimize patient triage and diagnostic accuracy. The company's core value proposition lies in its ability to bridge the gap between primary care and specialized dermatology through high-quality image capture and world-class diagnostic software. With FDA Breakthrough Device designations for its autonomous skin cancer AI, 3Derm is effectively transforming how healthcare providers manage skin-related pathologies, ensuring that clinical decision-making is supported by robust, data-backed evidence. The firm serves a diverse array of healthcare organizations, aiming to reduce the burden on specialists while improving patient outcomes through early detection and streamlined care pathways.
How much funding has 3Derm raised?
3Derm has raised a total of $2.8M across 2 funding rounds:
Private Equity
$1.2M
Private Equity
$1.7M
Private Equity (2014): $1.2M, investors not publicly disclosed
Private Equity (2016): $1.7M, investors not publicly disclosed
Key Investors in 3Derm
Undisclosed Investor
An institutional capital partner focused on scaling high-growth healthcare technology firms through strategic private equity financing.
Undisclosed Investor
A private equity firm specializing in the long-term development of medical device and diagnostic software companies.
Undisclosed Investor
A strategic investment group providing growth capital to companies at the forefront of digital health and clinical AI innovation.
What's next for 3Derm?
With the recent influx of capital, 3Derm is well-positioned to accelerate the commercialization of its AI-driven diagnostic tools and expand its footprint within the enterprise healthcare sector. The strategic roadmap likely involves scaling the deployment of its FDA-cleared technology across major hospital networks and integrated delivery systems. As the company transitions into this growth phase, the focus will shift toward deepening its clinical validation studies and refining its machine learning models to address a broader spectrum of dermatological conditions. By maintaining its commitment to technological innovation and clinical excellence, 3Derm is poised to set a new standard for autonomous diagnostic care, potentially reshaping the economics of dermatology and improving accessibility for patients globally.
See full 3Derm company page
